Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3121562rdf:typepubmed:Citationlld:pubmed
pubmed-article:3121562lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C1948058lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0021745lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0312418lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C1448177lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0042764lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:3121562lifeskim:mentionsumls-concept:C0036667lld:lifeskim
pubmed-article:3121562pubmed:issue11lld:pubmed
pubmed-article:3121562pubmed:dateCreated1988-2-23lld:pubmed
pubmed-article:3121562pubmed:abstractTextThe colony-inhibitory effects of recombinant human tumor necrosis factor (rH-TNF) and recombinant human interferon-gamma (rH-IFN-gamma) were evaluated in four human lung cancer cell lines and their cisplatin-resistant sublines. The cell lines tested were PC-7 and PC-9 (adenocarcinoma), H69 and N231 (small cell lung cancer) and four cisplatin-resistant sublines, PC-7/1.0, PC-9/0.5, H69/0.2 and N231/0.2, which were 20.0, 7.1, 4.8 and 8.4 fold resistant to cisplatin, respectively, compared to the respective parental cell line in terms of IC50 in a soft agar colony assay. All parental cell lines were resistant to rH-TNF and rH-IFN-gamma, alone or in combination. However, two resistant sublines showed sensitivity to rH-TNF and rH-IFN-gamma. Colony formation by PC-9/0.5 was significantly inhibited, in the absence or presence of cisplatin, by 10(2) U/ml of rH-TNF (less than 50% of control) and the inhibition was synergistic with that produced by 10(3) or 10(4) U/ml of rH-IFN-gamma. RH-IFN-gamma inhibited the colony formation of H69/0.2 only at the highest concentration tested (10(4) U/ml) (less than 50% of control) and the combined effect with rH-TNF was additive. These results suggest that rH-TNF and rH-IFN-gamma may have some potential in overcoming cisplatin resistance by virtue of collateral sensitivity.lld:pubmed
pubmed-article:3121562pubmed:languageenglld:pubmed
pubmed-article:3121562pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3121562pubmed:citationSubsetIMlld:pubmed
pubmed-article:3121562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3121562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3121562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3121562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3121562pubmed:statusMEDLINElld:pubmed
pubmed-article:3121562pubmed:monthNovlld:pubmed
pubmed-article:3121562pubmed:issn0910-5050lld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:NakagawaKKlld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:TakahashiHHlld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:SasakiYYlld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:TwentymanP...lld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:SakuraiMMlld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:NakanoHHlld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:SaijoNNlld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:EguchiKKlld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:ShinkaiTTlld:pubmed
pubmed-article:3121562pubmed:authorpubmed-author:HongW SWSlld:pubmed
pubmed-article:3121562pubmed:issnTypePrintlld:pubmed
pubmed-article:3121562pubmed:volume78lld:pubmed
pubmed-article:3121562pubmed:ownerNLMlld:pubmed
pubmed-article:3121562pubmed:authorsCompleteYlld:pubmed
pubmed-article:3121562pubmed:pagination1274-80lld:pubmed
pubmed-article:3121562pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:3121562pubmed:meshHeadingpubmed-meshheading:3121562-...lld:pubmed
pubmed-article:3121562pubmed:meshHeadingpubmed-meshheading:3121562-...lld:pubmed
pubmed-article:3121562pubmed:meshHeadingpubmed-meshheading:3121562-...lld:pubmed
pubmed-article:3121562pubmed:meshHeadingpubmed-meshheading:3121562-...lld:pubmed
pubmed-article:3121562pubmed:meshHeadingpubmed-meshheading:3121562-...lld:pubmed
pubmed-article:3121562pubmed:meshHeadingpubmed-meshheading:3121562-...lld:pubmed
pubmed-article:3121562pubmed:meshHeadingpubmed-meshheading:3121562-...lld:pubmed
pubmed-article:3121562pubmed:meshHeadingpubmed-meshheading:3121562-...lld:pubmed
pubmed-article:3121562pubmed:meshHeadingpubmed-meshheading:3121562-...lld:pubmed
pubmed-article:3121562pubmed:year1987lld:pubmed
pubmed-article:3121562pubmed:articleTitleIn vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity.lld:pubmed
pubmed-article:3121562pubmed:affiliationDepartment of Internal Medicine, Korea Cancer Center Hospital, Seoul.lld:pubmed
pubmed-article:3121562pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3121562pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed